Though volume declined by 10.5% yoy, ALL's reported revenue dipped by only 6.5% on the back of 3.9% yoy rise in ASPs. We attribute sharp rise in ASPs to higher non domestic M&HCV; revenue. Notably, non domestic M&HCV; businesses contributed ~45% to ALL's total revenue in 2QFY17 vs. 36% in 2QFY16. EBITDA margin contracted by 100bps yoy to...